<unk>  is a radiolabeled somatostatin analog that is FDA approved for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.   Common adverse reactions include lymphopenia, increased GGT, vomiting, nausea, increased AST, increased ALT, hyperglycemia and hypokalemia.
Lutetium Lu 177 dotatate
Lutetium lu 177 dotatate
Radium-223 chloride
Diodone
Technetium 
Clodronate
Cadexomer iodine
Copper usnate